Bioanalysis Zone

How to achieve sensitive and specific oligonucleotide quantification by hybrid immunoassay and LC–MS/MS


Oligonucleotide (OGN) therapy is increasingly recognized as an important therapeutic modality on the promise of curing diseases. However, unlike most biotherapeutics, the development of OGN drugs often requires their determination with high sensitivity and specificity in multiple, complex biologic matrices such as blood and tissues in order to measure their exposure and distribution for understating PK, PD and safety.

At Frontage Laboratories (PA, USA), we have developed highly sensitive and specific quantitative methods for determination of OGN in plasma and tissues using hybridization immunoassay and LC–MS techniques. In this webinar, we will present the method development, validation and comparison of these techniques for the quantification of OGN as well as a case study with antisense OGN.

What will you learn?

  • Bioanalysis of oligonucleotides in biological matrices (plasma, tissues)
  • Ultrasensitive quantification through hybridization based ECL assays
  • HPLC–MS/MS bioanalysis of oligonucleotides and metabolites
  • Pros and cons of hybrid immunoassays and LC–MS/MS
  • Fit-for-purpose method development and validation

Who may this interest?

  • Bioanalytical scientists
  • PK/PD scientists
  • Pharmaceutical researchers
  • Contract research providers
  • Bioanalytical method developers




Chenyi Pan, PhD
Group Leader, Biologics Services
Frontage Laboratories, Inc (PA, USA)


Dr Chenyi Pan is a group leader of Biologics Services at Frontage Laboratories, Inc (PA, USA). He received his BS from Zhejiang University, China, and his PhD in Biology from Georgia Institute of Technology (GA, USA). His PhD research was focused on the epigenetic regulation of stem cells and cancer. Before joining Frontage in 2017, Dr Pan worked as an NSF EBICS postdoctoral fellow in biomedical engineering at Georgia Tech, where he developed novel biosensor systems to monitor intracellular redox status during stem cell differentiation. At Frontage, Dr Pan is responsible for immunoassay development and validation, as well as communication with clients on deliverables. He has strong expertise in PK, immunogenicity and biomarker assays based on various platforms, including ELISA, MSD electrochemiluminescence, Quanterix Simoa and Ella. Working in a GLP- and CLIA-regulated environment, he has been helping biopharmaceutical companies with preclinical and clinical drug development in the fields of immuno-oncology, neurology, diabetes, etc.



Zhiling Zhang, PhD
Lab Manager, Bioanalytical Services
Frontage Laboratories, Inc (PA, USA)


Dr Zhiling Zhang is a lab manager of Bioanalytical Services at Frontage Laboratories, Inc (PA, USA). He received his BS and MS in Tsinghua University, China, and his PhD in Biology from Drexel University (PA, USA). His PhD research was focused on the development of drug delivery system for therapeutic protein and small molecular drugs. After joining Frontage in 2016, Dr Zhang continues to use LC–MS platforms to analyze large molecules, including antibody–drug conjugates (ADC), oligonucleotides, proteins and polysaccharide biomarkers. He has demonstrated strong expertise in affinity-capture, protein structure and LC–MS techniques. Under a GLP-regulated environment, Dr Zhang also works as principal investigator for method development, validation and sample analysis, supporting preclinical and clinical studies for multiple pharmaceutical companies.

In association with








Leave A Comment